He Shendi, Cao Beibei, Yu Hui, Zhen Junhai, Wang Fei
Electromyography Room, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, PR China.
Department of Pathology, Zhejiang Hospital, Hangzhou, Zhejiang, China.
Pak J Pharm Sci. 2020 Nov;33(6):2679-2686.
Previous studies have shown that selenium and its compounds play a role in immunomodulatory, antioxidant stress and so on. If selenium can improve the prognosis of patients with sepsis, it will be another weapon in the treatment of sepsis. At present, there are some randomized controlled trials (RCTs) about parenteral selenium for the treatment of sepsis. However, the results of those studies are not consistent. Studies were searched from electronic databases including PubMed, Cochrane, and Embase. RCTs which applied the selenium to septic patients as the inference measure were collected. After data extraction and the evaluation for eventual inclusion literatures, the data were analyzed by the statistical software RevMan 5.3. A total of 11 RCTs were included, containing 1916 septic patients. Meta-analysis showed that there is no statistically significant difference between the selenium group and the control group in mortality (RR=0.95, 95%CI=0.83-1.08, P=0.42), ICU length of stay (MD=1.56, 95%CI=-0.66-3.79, P=0.17) and new infections (RR=0.95, 95%CI=0.73-1.24, P=0.69). The present study suggests that there is no sufficient evidence that the parenteral selenium can improve the prognosis of septic patients.
先前的研究表明，硒及其化合物在免疫调节、抗氧化应激等方面发挥作用。如果硒能改善脓毒症患者的预后，它将成为治疗脓毒症的又一武器。目前，有一些关于肠外补充硒治疗脓毒症的随机对照试验（RCT）。然而，这些研究的结果并不一致。研究从包括PubMed、Cochrane和Embase在内的电子数据库中检索。收集了将硒应用于脓毒症患者作为干预措施的RCT。在进行数据提取和对最终纳入文献的评估后，使用统计软件RevMan 5.3对数据进行分析。共纳入11项RCT，包含1916例脓毒症患者。荟萃分析表明，硒组和对照组在死亡率（RR=0.95，95%CI=0.83 - 1.08，P=0.42）、重症监护病房（ICU）住院时间（MD=1.56，95%CI=-0.66 - 3.79，P=0.17）和新发感染（RR=0.95，95%CI=0.73 - 1.24，P=0.69）方面无统计学显著差异。本研究表明，没有足够的证据表明肠外补充硒能改善脓毒症患者的预后。
